S Samuel Weigt
Overview
Explore the profile of S Samuel Weigt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
755
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rim J, Hellkamp A, Neely M, Reynolds J, Belperio J, Budev M, et al.
J Heart Lung Transplant
. 2024 Dec;
PMID: 39642952
Background: Basiliximab induction immunosuppression is increasingly employed in lung transplant recipients despite limited prospective evidence to support its use in this population. We sought to determine the relationship between basiliximab...
2.
Amubieya O, Todd J, Neely M, Kaner R, Lasky J, Namen A, et al.
PLoS One
. 2024 Oct;
19(10):e0312044.
PMID: 39418259
Introduction: We assessed the prognostic utility of circulating levels of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in patients with idiopathic pulmonary fibrosis (IPF) in the IPF-PRO...
3.
Webb M, Wilson J, Samuel Weigt S, Sayah D, Nassiri N, Ardehali A, et al.
JACC Case Rep
. 2024 Oct;
29(17):102493.
PMID: 39359509
We present a patient with a history of lung transplantation who subsequently underwent dual heart-kidney transplantation for nonischemic cardiomyopathy and chronic kidney disease, becoming one of the rare cases of...
4.
Calabrese D, Tsao T, Magnen M, Valet C, Gao Y, Mallavia B, et al.
JCI Insight
. 2022 Nov;
7(24).
PMID: 36346670
Clinical outcomes after lung transplantation, a life-saving therapy for patients with end-stage lung diseases, are limited by primary graft dysfunction (PGD). PGD is an early form of acute lung injury...
5.
Belperio J, Samuel Weigt S, Lynch 3rd J
JAMA
. 2022 Jul;
328(1):78.
PMID: 35788797
No abstract available.
6.
Liang J, Huang G, Liu X, Taghavifar F, Liu N, Wang Y, et al.
J Clin Invest
. 2022 Apr;
132(11).
PMID: 35389887
Type 2 alveolar epithelial cells (AEC2s) function as progenitor cells in the lung. We have shown previously that failure of AEC2 regeneration results in progressive lung fibrosis in mice and...
7.
Belperio J, Shaikh F, Abtin F, Fishbein M, Samuel Weigt S, Saggar R, et al.
JAMA
. 2022 Mar;
327(9):856-867.
PMID: 35230389
Importance: Sarcoidosis is an inflammatory granulomatous disease of unknown cause that affects an estimated 2 to 160 people per 100 000 worldwide and can involve virtually any organ. Approximately 10%...
8.
Samuel Weigt S, Kim G, Jones H, Ramsey A, Amubieya O, Abtin F, et al.
Transplantation
. 2021 Sep;
106(6):1253-1261.
PMID: 34534193
Background: Chronic lung allograft dysfunction (CLAD) phenotype determines prognosis and may have therapeutic implications. Despite the clarity achieved by recent consensus statement definitions, their reliance on radiologic interpretation introduces subjectivity....
9.
Liu X, Rowan S, Liang J, Yao C, Huang G, Deng N, et al.
iScience
. 2021 Jun;
24(6):102551.
PMID: 34151224
Pulmonary mesenchymal cells are critical players in both the mouse and human during lung development and disease states. They are increasingly recognized as highly heterogeneous, but there is no consensus...
10.
Amubieya O, Ramsey A, DerHovanessian A, Fishbein G, Lynch 3rd J, Belperio J, et al.
Semin Respir Crit Care Med
. 2021 May;
42(3):392-410.
PMID: 34030202
The primary factor that limits long-term survival after lung transplantation is chronic lung allograft dysfunction (CLAD). CLAD also impairs quality of life and increases the costs of medical care. Our...